Saturday, September 23, 2023
Saturday, September 23, 2023

Texas Health Fort Worth’s Jane and John Justin Tower Set to Open April 2

Texas Health Fort Worth’s Jane and John Justin Tower opening caps a more than two-year-long, $300 million construction project that adds 400,000 square feet to the hospital.

The nine-story tower, which includes 144 beds, 15 surgery suites, and new pre- and postoperative suites services, is the largest construction project in Texas Health history.

Justin Tower reinforces Texas Health’s long-standing commitment to the Fort Worth community,” said Barclay Berdan, FACHE, CEO of Texas Health Resources and a former president of Texas Health Fort Worth. “What began as a small community hospital has evolved into a world-class medical center serving the 12th largest city in the U.S.”

Justin Tower will increase surgical capacity by almost 30%, with dedicated neurosurgery and orthopedics operating suites. The surgical suites are twice the size of existing operating rooms (ORs) to accommodate modern robotic and imaging technology and are sized to accommodate even larger equipment in the future.

“Our service area includes 1.2 million people in four counties, and that’s expected to grow by another 100,000 over the next five years,” said Joseph DeLeon, president of Texas Health Fort Worth. “The larger, more modern facilities allow us to treat this growing population with specialty services, including trauma, neuroscience, heart and vascular, and many others.”

In addition to the ORs, additional elements of Justin Tower were built with an eye to the future. All patient rooms are private and can be modified to provide varying levels of care, from general medical-surgical to critical care. Additional design elements include the use of natural light, patient-friendly way-finding, and indoor and outdoor spaces for visitors.

 

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

FDA Grants Fast Track Designation to 9MW3011

9MW3011 has been approved to clinical study by NMPA and FDA, respectively. The first person has been dosed in the clinical study in China in March, 2023.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

"We are pleased to gain the QIDP and Fast Track designations for DFI as recognition that contezolid and contezolid acefosamil are novel new agents to meet an important unmet need in this common and challenging infection", stated Dr Zhengyu Yuan, Chief Executive Officer at MicuRx. 

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) Application for VNT-101

"We look forward to evaluating VNT-101 in the clinic," said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. "This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."

FDA OK’s ensoETM for Use in Cardiac Ablations to Reduce Risk of Esophageal Injury

Published studies that have examined the use of ensoETM for this purpose include the pilot eCOOL-AF study, the IMPACT study and a large multi-center analysis of over 25,000 patients (in press at the Journal of the American College of Cardiology: Clinical Electrophysiology). These studies have found up to an 83 percent reduction in esophageal injuries, and a significant reduction in risk of atrioesophageal fistula (AEF), one of the most dreaded complications of ablation procedures.

Annalise.ai Receives FDA Clearance and Breakthrough Device Designation

Annalise.ai has also received FDA Breakthrough Device Designation for its obstructive hydrocephalus software tool. This is the first radiology triage device to be granted Breakthrough status since the inception of the FDA Breakthrough Devices Program.

By using this website you agree to accept Medical Device News Magazine Privacy Policy